29 results on '"Doz F"'
Search Results
2. 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
3. 667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
4. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
5. 463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
6. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
7. European collaboration in trials of new agents for children with cancer
8. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy
9. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d'Oncologie Pédiatrique
10. 534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
11. 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
12. 366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
13. 365O - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
14. 445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
15. 69O - Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
16. 409O - Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
17. 418TiP - Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer
18. 807 Experimental Therapeutic Approach of Orthotopic and Subcutaneous Human Retinoblastoma Xenografts by the Human Anti-VEGF Antibody Bevacizumab, Alone or in Combination With Carboplatin
19. 778 Development and Pharmacological Assessment of New Models of Orthotopic Primary Human Uveal Melanoma and Retinoblastoma Xenografts
20. 99 SIOP brain tumour trials
21. 86 Ethical aspects of early phase clinical trials in children
22. 248/249 INVITED Clinical phase I-II and pharmacokinetic study of plitidepsin in children with malignant tumors
23. 246 INVITED Imatinib mesylate in recurrent solid tumours expressing KIT or PDGFR (phase II)
24. 185 French adaptation of the health utilities index (HUI): A health-related quality of life instrument, in children with brain cancer
25. N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma
26. Metastatic medulloblastoma: the experience of the French cooperative M7 group
27. 260 High-dose chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT) in place of craniospinal irradiation (RXT) in young children treated for medulloblastoma (MB)?
28. 267 Chemotherapy for low grade gliomas
29. 256 Chemotherapy without irradiation (RT) in medulloblastoma patients younger than three. A prospective study by the French society of pediatric oncology (SFOP)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.